MBA (Wharton), GAICD

Stephane Chatonsky is a seasoned leader with over 25 years experience in venture capital, private equity, investment banking, strategy and strategic advisory services.

He has held executive positions with globally recognised organisations, including Lazard, McKinsey & Co, Macquarie Bank and LeapFrog Investments.

Throughout his career, Stephane has served as a Non-Executive Director, Chair, and advisor to leading firms in the pathology, healthcare, and technology sectors.

His entrepreneurial spirit, coupled with a pragmatic leadership style, has been instrumental in steering pivotal business and capital decisions that drive growth.

Stephane is committed to education and mentoring, contributing his insights and expertise at Macquarie University and the University of New South Wales’ MBA program, as well as through The CEO Institute’s leadership programs.

His open and clear communication style fosters trusted relationships with executive teams, board members, and investors.

Currently, Stephane is the Co-Founder and Managing Director of IVEST, Board Chair of Brainmates, Non-Executive Director of Genetic Signatures (ASX: GSS), Drop Bio Health, and Neo-Bionica.

He also serves as Chair at The CEO Institute, Honorary Fellow at Macquarie University, Adjunct Professor at the University of New South Wales, and an Expert Witness to the Federal Court of Australia.

Stephane is a graduate of ESSEC (Paris) holds an MBA from Wharton (University of Pennsylvania) and is a graduate of the Australian Institute of Company Directors.

BAppSc(MedLabSc), PhD, FASN

Professor Darren Kelly is the Managing Director, Chief Executive Officer and Founder of Certa Therapeutics and Founder and Executive Chair of OccuRx, bringing over 25 years of management and research expertise in the life sciences and biotech sector. Concurrent to his Certa Therapeutics and OccuRx roles, Professor Kelly is the Director of Biomedical Research in the Department of Medicine, University of Melbourne, where his research expertise lies in progressing pre-clinical novel interventions and developing experimental models of cardiovascular disease.

Professor Kelly  has published over 200 manuscripts in the field of translational research and novel interventions many of which have had a direct impact on human disease. In 2009, Professor Kelly was a recipient of the prestigious TJ Neale award for outstanding contribution to nephrology. In 2015 he joined the Medical Research Commercialisation Fund as Venture Partner and is a Non executive Director on a number of Boards.

Professor Kelly has proven history in translational research. He was previously Founder, CEO and Director of Fibrotech Therapeutics, a company that developed orally active anti-fibrotic inhibitors to treat underlying pathological fibrosis in kidney and heart failure, which was ultimately acquired by Shire Plc for a record 75 million USD upfront including milestone payments up to 600 million USD.

He has a PhD in Translational Medicine from the University of Melbourne. He is a current member of the Australian Institute of Company Directors, AusBiotech, BioMelbourne Network and a Fellow of the American Society of Nephrology.

MA, BM, BCh, DM, MRCP, FRCOphth, FRANZCO, FARVO, FAAPPO, ALCM

Professor Keith Martin is Managing Director of the Centre for Eye Research Australia (CERA) and Ringland Anderson Professor and Head of Ophthalmology at the University of Melbourne.

He is also Honorary Senior Research Fellow at the University of Cambridge, Honorary Professor of Ophthalmology at the University of Sydney and a Senior Visiting Medical Officer for the Glaucoma Unit at Royal Victorian Eye and Ear Hospital. Clinically, Professor Martin specialises in the medical and surgical management of complex glaucoma. He is immediate Past President of the World Glaucoma Association (WGA), the largest glaucoma organisation in the world, and remains a Governor of WGA. He is President of the Australia and New Zealand Glaucoma Society.

Professor Martin  is working to develop new treatments for eye disease using stem cells, gene therapy and other techniques as a Principal Investigator at CERA.

He is co-founder of Quethera, a Cambridge-based gene therapy company which has developed a gene therapy for glaucoma that is currently progressing towards human clinical trials. He is also co-founder of Ikarovec, a second gene therapy spin out company from his lab developing gene therapies for common retinal diseases, and a Director of Enlighten Imaging, a CERA spin-out company.

Associate Professor Tina Soulis has over 28 years of working in the healthcare (pharmaceuticals and devices), biotechnology, academic research, clinical research and management sectors in senior roles including: CEO of a Contract Research Organisation, Director of a successful ASX200 company, VP of Clinical Strategy and Development with an innovative biotechnology company and now, founder and director of her own full-service capability clinical CRO.

A dynamic and strategic leader, Associate Professor Soulis has an extensive network of stakeholders all over the world and experience in many therapeutic areas across all phases on development.

She holds academic appointments with the University of Melbourne (teaching and supporting undergraduate pharmacology, Masters in Leadership in Science and Master in Commercialisation in Science students).

Passionate about mentoring future industry leaders and advocating for the Australian R&D community, Associate Professor Soulis serves on several therapeutic executive advisory boards, as Australian resident director to a portfolio of overseas entities and advisors many US-based biotechnology companies.

She is a regular invited speaker locally and globally on a broad range of topics on clinical trials, research, innovation and industry collaboration.

Recently, Associate Professor Soulis launched Alithia Life Sciences, where her motivation and mission is to work with her clients to deliver efficient accomplishment of their project, add value to their programs and to ultimately enable improvement of human health and wellbeing.

Associate Professor Soulis is also VP of Clinical Strategy and Development for Kinoxis Therapeutics Pty Ltd, an innovative NIH/NIDA backed biotechnology company developing novel therapies for unmet neurological conditions.

Associate Professor Soulis is one of the few Australian clinical development leaders who has successfully taken products from lab to regulatory approval.

Our leadership team includes deep expertise in trial governance, design and delivery, as well as the use of ethical digital technologies to boost trial recruitment and retention.